Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

Fig. 3

SCD1 re-activates Gefitinib-impaired migration and invasion in lung cancer. The A549 and H1573 cells with or without SCD1 overexpression were treated with Gefitinib (20 μM) and A939572 (1 nM), and the migration and invasion of the cells were assessed by Transwell assay. *p < 0.05, **p < 0.01, data is presented as mean ± sd

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us